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Abstract
Background: Taurine upregulated gene1 (TUG1) as a 7.1-kb lncRNA, has been shown to play an oncogenic role in
various cancers. However, the biological functions of lncRNA TUG1 in small cell lung cancer (SCLC) remain
unknown. The aim of this study is to explore the roles of TUG1 in cell growth and chemoresistance of SCLC and its
possible molecular mechanism.
Methods: The expression of TUG1 in thirty-three cases of SCLC tissues and SCLC cell line were examined by
quantitative RT-PCR (qRT-PCR). The functional roles of TUG1 in SCLC were demonstrated by CCK8 assay, colony
formation assay, wound healing assay and transwell assay, flow cytometry analysis and in vivo study through siRNA
or shRNA mediated knockdown. Western blot assays were used to evaluate gene and protein expression in cell
lines. Chromatin immunoprecipitation (ChIP) and RNA binding protein immunoprecipitation (RIP) were performed
to confirm the molecular mechanism of TUG1 involved in cell growth and chemoresistance of small cell lung
cancer.
Results: We found that TUG1 was overexpressed in SCLC tissues, and its expression was correlated with the clinical
stage and the shorter survival time of SCLC patients. Moreover, downregulation of TUG1 expression could impair
cell proliferation and increased cell sensitivity to anticancer drugs both in vitro and in vivo. We also discovered that
TUG1 knockdown significantly promoted cell apoptosis and cell cycle arrest, and inhibited cell migration and
invasion in vitro . We further demonstrated that TUG1 can regulate the expression of LIMK2b (a splice variant of
LIM-kinase 2) via binding with enhancer of zeste homolog 2 (EZH2), and then promoted cell growth and
chemoresistance of SCLC.
Conclusions: Together, these results suggested that TUG1 mediates cell growth and chemoresistance of SCLC by
regulating LIMK2b via EZH2.
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Background
Small-cell lung cancer (SCLC) is a highly lethal malig-
nancy that accounts for 10–15% of lung cancers [1].
SCLC is characterized by a rapid doubling time, high
growth fraction, and early development of widespread
metastases [2]. Although the incidence of SCLC is re-
portedly decreasing over time, 5-year survival rates is
still lower than 10%[3]. SCLC is highly sensitive to initial
chemotherapy and radiotherapy; however, most patients
eventually die of widespread metastasis and rapid devel-
opment of chemoresistance to chemotherapy [4, 5]. In
addition, though genetic changes have been reported in
SCLC [6], the precise molecular mechanisms involved in
SCLC development and chemoresistance remain to be
fully elucidated.
Recently, research has postulated a class of non-
protein-coding RNAs (ncRNAs) that longer than 200
nucleotides in length, defined as long non-coding RNAs
(lncRNAs), participates in cell biological processes and
human disease pathogenesis [7, 8]. lncRNAs are poorly
conserved and regulate gene expression at various levels,
such as chromatin modification, transcription and post-
transcriptional processing [9, 10]. With more and more
studies on lncRNA, some researchers classify lncRNA
for five broad categories: sense, antisense, bidirectional,
intronic, intergenic; and summarize four known molecu-
lar functions of lncRNAs: signal, decoy, guide, and scaf-
fold [11]. Interestingly, increasing evidence suggests that
lncRNAs play a important role in tumorigenesis, and
their aberrant expression confers tumor initiation, can-
cer cell growth and apoptosis, chemoresistance, invasion
and metastasis [12–14]. For example, promotion of lung
cancer metastasis by lncRNA MALAT1 (Metastasis As-
sociated Lung Adenocarcinoma Transcript 1); control of
hepatocellular cancer cell growth and apoptosis by
MEG3; regulation of oesophageal adenocarcinoma cell
proliferation and migration by HNF1A-AS1 [15–17]. In
addition, studies showed that the long non-coding RNA
HOTTIP promotes gemcitabine resistance by regulating
HOXA13 in pancreatic cancer [14]. Our laboratory also
reported that lncRNA HOTAIR affects chemoresistance
by regulating HOXA1 methylation in SCLC [18]. How-
ever, functional roles of lncRNAs in SCLC have not been
well documented.
The TUG1 (Taurine upregulated gene) lncRNA, lo-
cated at chromosome 22q12, was originally identified as
a transcript up-regulated by taurine [19]. Recently, accu-
mulating evidence has shown that TUG1 is a negative
prognostic factor for osteosarcoma patient survival, and
high expression of TUG1 in patients has been correlated
with enhanced bladder and esophagus cancer cells pro-
liferation and metastasis [20–22]. In previous study, re-
searcher found TUG1 could induced by p53, then binds
to PRC2, and play a key role in cell-cycle regulation [23].
Some studies have explored that TUG1 may regulate
genes expression through binding to PRC2. For instance,
TUG1 could regulate the expression of HOXB7 by bind-
ing to PRC2, then affects cell proliferation in human
non-small cell lung cancer [24]. In gastric cancer, TUG1
epigenetically silencing of p57 by binding with PRC2 to
regulates cell proliferation [25]. However, little is known
about TUG1 in SCLC.
In this study, we attempted to explore the potential in-
volvement of TUG1 in SCLC. We found that TUG1 was
upregulated in SCLC tissues than matched adjacent nor-
mal tissues and its upregulation is related with poor
prognosis. Knockdown of TUG1 impairs proliferation,
migration, invasion and induces cell apoptosis and cell-
cycle arrest of human SCLC cell lines. Moreover, we
identify the role of TUG1 in chemoresistance in SCLC
cells for the first time. Additionally, we found TUG1
affect cell growth and chemoresistance by regulating
LIMK2b expression via binding with EZH2. Taken to-
gether, our findings suggest that TUG1 may be a novel
potential molecular target for treating SCLC patients.
Results
The expression of TUG1 increased in SCLC tissues and
was associated with clinical stage and survival
To investigate the clinicopathological features of TUG1
expression in SCLC, qRT-PCR was performed in 33
tumor samples from SCLC patients. TUG1 expression
level was significantly higher in SCLC tumor tissues than
those in normal counterparts (P < 0.01) (Fig. 1a). Table 1
summarizes the correlation between TUG1 expression
and clinicopathological parameters of SCLC patients.
The data indicated that higher expression of TUG1 in
extensive disease-SCLC (ED-SCLC) than in limited dis-
ease SCLC (LD-SCLC) (P = 0.011). Specifically, we ob-
served higher expression of TUG1 in smoking patients.
Kaplan-meier survival analysis based on TUG1 expres-
sion showed that high TUG1 expression was correlated
with poorer patient survival (Fig. 1b). However, no sig-
nificant difference was observed with respect to sex (fe-
male and male) and age (≤62 years and >62 years) in our
study. Taken together, these results indicated that TUG1
overexpression in SCLC tissues was correlated with stage
and survival of SCLC patients.
TUG1 was upregulated in SCLC cell lines and affected cell
proliferation in vitro and in vivo
To further investigate the role of TUG1 in SCLC cells,
we evaluated the expression of TUG1 in SCLC cell lines
(H69, H69AR, H446, H446DDP) and in the normal
bronchial epithelial cell line (16HBE) by qRT- PCR. As
shown in Fig. 2a, all SCLC cell lines expressed high
levels of TUG1 compared with 16HBE. We then tested
whether TUG1 was functionally involved in SCLC cell
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growth. We first designed three different TUG1
siRNAs to transfect these four cell lines. qRT-PCR
analysis was conducted at 24 h post-transfection
and showed that siTUG1 1* and siTUG1 2* had
higher efficiency of interference than siTUG1 3*
(Additional file 1: Figure S1 A-D). Then we chose
siTUG1 1* and siTUG1 2* for the following experi-
ments (Fig. 2b). Moreover, we also established
stable TUG1 knockdown SCLC cell lines by retro-
virus infection (Fig. 2c). CCK-8 assay and colony
formation assay were used to detect the effect of
TUG1 knockdown on growth of the SCLC cell
lines. As shown in Fig. 2d, SCLC cells transfected
with siTUG1 showed greatly reduced cell prolifera-
tion rate. Similarly, the colony formation assay
demonstrated that the number of colonies de-
creased significantly in SCLC cells transfected with
shTUG1 as compared with shControl (Fig. 2e).
The tumorigenic properties of TUG1 in vivo were per-
formed in male nude mouse xenograft. We injected
H446 and H69 cells transfected with either shControl or
shTUG1 into nude mice. As shown in Fig. 3a-c, down-
regulation of TUG1 significantly inhibited tumor growth.
We also performed qRT-PCR to detect the expression of
Table 1 Association of TUG1 expression and clinicopathological characteristics in 33 SCLC patients
Characteristics Total
(n = 33)
TUG1 expression χ2 P value*
Low expression High expression
Gender 1.816 0.174
Male 26 15 (57.7) 11 (42.3)
Female 7 2 (50.0) 5 (50.0)
Age (years) 0.299 0.420
≤62 year 19 9 (47.4) 10 (52.6)
>62 year 14 8 (57.1) 6 (42.9)
Smoking history 3.529 0.032
YES 20 7 (35.0) 13 (65.0)
NO 13 10 (76.9) 3 (23.08)
Disease stage 6.651 0.011
Limited disease (LD) 16 12 (75.0) 4 (25.0)
Extensive-stage disease (ED) 17 5 (29.4) 12 (70.6)
Status 4.520 0.036
Survival 10 8 (80.0) 2 (20.0)
Death 23 9 (39.1) 14 (60.9)
*For analysis of correlation between of TUG1 expression levels and clinical features, Fisher’s Exact Test were used. Results were considered statistically significant
at P <0 .05
Fig. 1 Relative TUG1 expression and its clinical significance in SCLC tissues. a The expression levels of TUG1 in SCLC tissues (n = 33) and adjacent
non-tumor tissues (n = 11). b Kaplan–Meier analysis of overall survival of 33 patients with SCLC based on TUG1 expression
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TUG1 in tumor tissues selected from mice (Fig. 3d). Re-
sults showed that the expression levels of TUG1 in the
shTUG1 group were lower than those in the control
group. Taken together, these data suggested the TUG1
affects SCLC cell proliferation and growth.
TUG1 involved in SCLC cell migration and invasion
Wound healing assay and transwell assay were per-
formed to investigate whether TUG1 had a functional
role in cell migration and invasion in SCLC. Result of
wound healing assay demonstrated the migration
Fig. 2 TUG1 was up-regulated in SCLC cell lines and TUG1 knockdown inhibited cell proliferation in vitro. a The expression of TUG1 was assessed
in SCLC cell lines compared with the normal bronchial epithelial cell line (16HBE) by qRT-PCR. b c Inhibition of TUG1 by transfection of TUG1
siRNAs or sh RNA in H69、H69AR、H446、H446DDP cells. d CCK-8 proliferation assays were used to determine the cell viability for siTUG1
transfected SCLC cells. Experiments were performed in triplicate. e Colony formation assays were performed to determine the proliferation of
shTUG1 transfected H446, H446DDP and H69AR cells. Representative photographs are shown, and the numbers of colonies were counted.
*, P < 0.05; **, P < 0.001
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distance of SCLC cells infected by shTUG1 was
significantly wider than the shControl group
(Additional file 2: Figure S2 A). In the transwell
assay, the number of shTUG1 infected cells that mi-
grated through the membrane were significantly less
than the shControl group (Additional file 2: Figure
S2 B). These results showed that inhibition of TUG1
could significantly impair SCLC cell migration and
invasion ability compared with control group.
TUG1 regulated cell apoptosis and cell cycle in SCLC cells
To further probe the potential mechanisms underlying
the growth-inhibitory effects of TUG1 knockdown, we
assessed cell apoptosis and cell-cycle in H446 and H69
Fig. 3 Effects of TUG1 knockdown on tumor growth in vivo. a Tumors formation of cells stably with lowTUG1 expression (N = 5 mice for each
group). b Growth curve of tumor volumes. c Tumor weights were determined. d qRT-PCR was conducted to detect the expression of TUG1.
*, P < 0.05; **, P < 0.001
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cells. Flow cytometry analysis demonstrated that TUG1
knockdown led to a significant increase of cell apoptosis (P
< 0.05) and a significant accumulation of cells at G1-phase
(P < 0.001, Additional file 3: Figure S3 A and B). These data
suggested that TUG1 mediated promotion of SCLC cell
growth may be mediated by regulation of the apoptosis and
G1-phase . Moreover, to investigate the possible mecha-
nisms of TUG1 in chemoresistance, we also conducted flow
cytometry analysis to examine the impact of TUG1 on
apoptosis when exposed to chemotherapeutic drugs. The
results showed that downregulation of TUG1 in H446DDP
and H69AR cells resulted in increased drug-induced apop-
tosis after treatment with ADM, DDP or VP-16 (Additional
file 4: Figure S4).
TUG1 expression was associated with SCLC
chemosensitivity in vitro and in vivo
To further investigate the impact of TUG1 on SCLC che-
mosensitivity, we detected the differential expression of
TUG1 in SCLC drug-sensitive cells (H69 and H446) and
drug-resistant cells (H69AR andH446DDP) by qRT-PCR.
The results showed that TUG1 over-expression in H69AR
and H446DDP cells than that in H69 and H446 cells
(Fig. 2a). After knockdown of TUG1, the IC50 values of
H446DDP and H69AR cells significantly decreased with
treatment of chemotherapeutic drugs including DDP, ADM
or VP-16 (Fig. 4a).
We then used a nude mouse xenograft model to further
investigate the ability of TUG1 to confer chemoresistance in
SCLC. H446DDP cells transfected with shTUG1 or shCon-
trol were subcutaneously injected into mice. As shown in
Fig. 4b, tumor growth was inhibited in the shTUG1 group
treated with PBS or drugs (DDP and VP-16) compared with
the controls. Tumor grew significantly more slowly in mice
following combined drugs treatment and TUG1 knock-
down. Four weeks later, the mean tumor volume for the
TUG1-knockdown group and the drugs group was obvi-
ously smaller than that of the control group (Fig. 4c). More-
over, combined treatment with TUG1 knockdown and
drugs led to an even further reduction in tumor volume.
Similarly, the average tumor weight in shTUG1 group com-
bined treatment with drugs showed a similar trend (Fig. 4d).
qRT-PCR analysis of TUG1 expression found it to be signifi-
cantly lower in tumor tissues formed from shTUG1 group
than those from controls (Fig. 4e). These results suggested
that downregulation of TUG1 increased the in vivo chemo-
sensitivity of H446DDP cells to drugs.
TUG1 affected cell growth and chemoresistance of SCLC
by regulating LIMK2b expression
To determine how TUG1 affects cell growth and che-
moresistance of SCLC, we conducted the bioinformatics
analysis to identify its potential downstream target
genes. We first searched the database and found that
TUG1 was previously identified to have an enhancer-like
function and positive influence on the neighboring
protein-coding genes [26]. We then predicted 12 TUG1
nearby coding genes (distance <300 kb) including
LIMK2b by searching UCSC Genome database (http://
genome.ucsc.edu/). Finally, we confirmed LIMK2b may
be the potential target gene in SCLC according to our
cDNA microarray analysis in which 1.5-fold upregula-
tion in drug resistance SCLC cells as compared to the
parental SCLC cells. We further performed qRT-PCR
and Western blot analysis to confirm our supposition.
The results showed that knockdown of TUG1 can in-
hibit LIMK2b expressions both at mRNA and protein
levels in H446DDP and H69AR cells (Fig. 5a).
We next examined whether LIMK2b played an important
role in TUG1 mediated cell growth and chemoresistance by
rescue experiments. Transfection of LIMK2b-GFP in
H446DDP and H69AR cells completely reversed the down-
regulation of LIMK2b induced by TUG1 (Fig. 5a). CCK8
and colony formation assay results suggested that cotransfec-
tion can partially rescue shTUG1 impaired proliferation and
chemoresistance (Fig. 5c and d). These results indicate that
TUG1 promotes SCLC cell proliferation and chemoresis-
tance partly through downregulation of LIMK2b expression.
Subsequently, we detected the relationship of TUG1
and LIMK2b in SCLC FFPE tissues. Consistent with the
results obtained from SCLC cell lines, LIMK2b was over-
expressed in SCLC tissues and the expression levels of
LIMK2b were positively correlated with those of TUG1 by
qRT-PCR in 33 SCLC FFPE tissues (Fig. 6a and b).
TUG1 regulated LIMK2b expression by binding with EZH2
On the basis of the study above, we found that TUG1 could
regulate the expression of LIMK2b, then we test whether
TUG1 has a direct combination with LIMK2b. However, the
result of RIP analysis showed no direct combination between
TUG1 and LIMK2b (Fig. 6c). TUG1 was previously reported
to mediated transcriptional regulation through binding with
EZH2 [23–25, 27]. Then we suppose that TUG1 may regu-
late LIMK2b expression by binding with EZH2. We designed
three different EZH2 siRNAs and to transfect H446DDP and
H69AR cells (Additional file 1: Figure S1 E-F). To further
confirm the results, we also applied EZH2 inhibitors EI1 or
GSK343 to treat H446DDP and H69AR cells. The results
showed that LIMK2b level was downregulated after EZH2
expressions were inhibited (Fig. 6d and e).
Furthermore, we conducted ChIP assays and found
that knockdown of TUG1 decreased the binding of
EZH2 and H3K27me3 levels across the LIMK2b pro-
moter compared to cells transfected with siNC (Fig. 6f ).
Taken together, these data suggest that TUG1 is re-
quired to target EZH2 occupancy and activity to epige-
netically modulate the expression of LIMK2b.
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Discussion
Recently, the study about the biological function of
TUG1 has become one of the hottest topics in various
cancer. TUG1 was overexpressed in various solid tumor
including osteosarcoma, bladder, esophagus, gastric and
liver cancer [20–22, 25, 27]. Nonetheless, the clinical
features of TUG1 expression in SCLC have not been re-
ported yet. In this study, we analyzed the expression of
TUG1 in 33 cases of human SCLC tissues and found
that the high expression level of TUG1 indicates shorter
Fig. 4 Knockdown TUG1 enhanced the chemosensitivity of SCLC cells to anticancer drugs both in vitro and in vivo. a The sensitivities of cells to
chemotherapy drugs (CDDP, ADM or VP-16) were measured after H69AR and H446DDP cells transfected with siTUG1 by CCK-8 assay. b Tumors
from all mice in each group (Each group has five mice). H446DDP cells were transduced with shControl or shTUG1 as indicated. After cells (3x107)
were injected into mice, chemotherapeutics or PBS were injected intraperitoneally as indicated. c Growth curve of tumor volumes. d Tumor
weights were determined. e qRT-PCR was conducted to detect the average expression of TUG1. *, P < 0.05; **, P < 0.001
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survival time of the SCLC patients. Therefore, our re-
search may provide an independent prognostic factor for
SCLC patients.
To explore the functional role of TUG1 in SCLC, we
therefore established stable TUG1-downexpressed cells
in the study. Our data indicate that TUG1 was upregu-
lated in SCLC, inhibition of TUG1 expression resulted
in decreased cell growth and enhanced chemosensitivity
both in vitro and in vivo. Moreover, we found that
knockdown of TUG1 also increased cell apoptosis, G1
Fig. 5 TUG1 affected cell growth and chemoresistance of small cell lung cancer by regulating LIMK2b. a qRT-PCR and western blot analysis for
LIMK2b in H446DDP-shTUG1 and H69AR-shTUG1 cells transfected with LIMK2b-GFP (NC, LIMK2b-GFP). b CCK-8 proliferation assay were used to
determine the cell viability (knockdown TUG1 while overexpression LIMK2b). c Representative images of Colony formation assays for proliferative
cells knockdown TUG1 while overexpression LIMK2b. d Survival of H446DDP and H69AR cells transfected with shTUG1 while overexpression
LIMK2b significantly increased compared with those transfected with negative control or mock transfected after treatment of CDDP, ADM
or VP-16
Niu et al. Molecular Cancer  (2017) 16:5 Page 8 of 13
cell-cycle arrest, and impaired SCLC cell migration and
invasion ability.
To further investigate the mechanisms of TUG1 in-
volved in cell growth and chemoresistance, we con-
ducted the bioinformatics analysis and found
LIMK2b, which located at 300kp of TUG1. LIMK2 is
a member of LIM kinase (LIMK) family that includes
LIMK1. LIMK2 encodes a kinase that regulates actin
dynamics through phosphorylation of cofilin, and
comprises two alternative transcripts, LIMK2a and
LIMK2b [28–30]. Recent reports illustrate that LIMK2
is involved in tumor growth, and induces migration
and invasion of tumor cells [31–33]. Additionally,
studies also showed a negative correlation between
LIMK2 and anticancer drugs, which suggesting that
LIMK2 may be a predictive marker of drug resistance
Fig. 6 TUG1 regulated LIMK2b expression by binding with EZH2. a Expression of LIMK2b in SCLC FFPE tissues by qRT-PCR. b The correlation of
LIMK2b and TUG1 expression in FFPE tissues. c RIP experiments were performed in H69AR cells and the coprecipitated RNA was subjected to
qRT-PCR for TUG1. The fold enrichment of TUG1 in LIMK2b RIP is relative to its matching IgG control. d e qRT-PCR and western blot analysis for
LIMK2b in H446DDP, H69AR cells inhibited EZH2 with EI1 or GSK343 or transfected with siRNA targeting EZH2 (si-NC, si-EZH2 1* and si-EZH2 2*).
f ChIp-qPCR of EZH2 occupancy and H3K27me3 binding in the promoters of LIMK2b in H69AR cells treated with siNC or si-TUG1; IgG as a
negative control. *P < 0.05, **P < 0.001
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[34, 35]. Previous study showed that LIMK2b could
encode only one and a half LIM domains after the
first LIM domain partially replaced, which is special
to the LIMK2 gene and conserved between murine
and human genes [36, 37]. Recent studies demon-
strated that LIMK2b is a direct target of p53 and in-
volved in the control of cell proliferation and cell
division. The report also showed that LIMK2b has a
critical role in promoting the G2/M DNA-damage
checkpoint [38]. In the present study, we firstly hy-
pothesized that TUG1 may associated with LIMK2b.
Our results showed that knockdown of TUG1 signifi-
cantly decrease the expression of LIMK2b. Further-
more, the impacts of TUG1 on cell growth and
chemoresistance were reversed by concomitant
LIMK2b -GFP, which indicating that the effect of
TUG1 on cell growth and chemoresistance is partly
mediated through LIMK2b. Moreover, we also found
that LIMK2b was over- expressed and positively cor-
related with TUG1 in SCLC tissues. However, RIP
analysis indicated that there was no direct combin-
ation between TUG1 and LIMK2b, which suggested
that TUG1 affected cell growth and chemoresistance
is not directly through LIMK2b. The results stated
above raises an interesting question: What is the
linker between TUG1 and LIMK2b? Several recent
studies indicated that TUG1 regulate genes expression
by binding with EZH2 to affect cell proliferation in
human non-small cell lung cancer, gastric cancer and
hepatocellular carcinoma [24, 25, 27]. So, we hypothe-
sized that EZH2 may be a linker between TUG1 and
LIMK2b. To prove our hypothesis, we used ChIP as-
says to demonstrate that knockdown of TUG1 de-
creased the binding of EZH2 and H3K27me3 levels
across the LIMK2b promoter. EZH2 as an important
component of polycomb repressive complex2 (PRC2)
has been reported to be necessary for the formation
of the H3K27me3, and recruits histone deacetylases
then resulting in gene transcriptional repression in
cancer cells [39–41]. These results suggested that
TUG1 epigenetically regulated LIMK2b through
EZH2.
Conclusions
In summary, our study showed that TUG1 was upregu-
lated in SCLC tissues and its overexpression is closely
associated with clinical stage and overall survival in pa-
tients with SCLC. Furthermore, the effects of TUG1 on
cell proliferation, cell apoptosis, cell cycle regulation, mi-
gration, invasion and chemoresistance indicated that
TUG1 promotes tumorigenesis. We also demonstrated
that TUG1 is involved in cell growth and chemoresis-
tance of SCLC through regulating LIMK2b by binding
with EZH2. This study may provide a strategy and lead
to the development of lncRNAs directed diagnostics and
therapeutics against SCLC.
Methods
Patients and tissue samples
A total of 33 formalin-fixed, paraffin-embedded (FFPE)
tissues (33 primary cancerous, 11 adjacent non cancerous
tissues) were collected from patients who had underwent
bronchofiberscopy or biopsy for SCLC between the period
2009.1 and 2013.11 and receiving care and follow-up at
The First Affiliated Hospital of Hebei North University,
informed consent was obtained from all patients before
sample collection. The experiments were approved by the
Ethics Committee of The First Affiliated Hospital of Hebei
North University, and conformed to the standards set by
the Declaration of Helsinki. Clinical data included the pa-
tient gender, age, smoking history, limited- or extensive-
stage disease and follow-up (Table 1).
Cell culture and treatment
Human SCLC cell line NCI-H69, NCI-H446, NCI-
H69ARwere purchased from the American Type Culture
Collection (ATCC, United States of America (USA)) and
maintained in RPMI1640 medium contain in L-glutam-
ine with 10% and 20% fetal calf serum respectively in an
incubator at 37 °C with 5% CO2. The cisplatin-resistant
NCI-H446DDP cell line was obtained by culturing cells
in gradually increasing doses of cisplatin up to 2.0 uM
after a total of 7 months in our laboratory. The drug-
resistant cells were maintained in drug-free medium for
at least 2 weeks before any experiment. To inhibit EZH2
activities, cells were treated with 12 μM GSK343 (S7164,
Selleck) or 10 μM EI1 (S7611, Selleck) for 36 h.
RNA isolation, quantitative reverse transcription-
polymerase chain reaction (qRT- PCR)
Total RNA was extracted from cell lines and FFPE tis-
sues using TRIzol (Invitrogen), RNeasy FFPE Kit (Qia-
gen) according to the manufacturer’s instructions.
According to Prime Script RT reagent Kit (TIANGEN,
Beijing, China), reverse transcription reactions were
processed at 42 °C for 15 min, followed by 3 min at 95 °
C for cDNA synthesis. Then quantitative real time PCR
was performed in an ABI illumina instrument . Primers
were designed by Shanghai Sangon Biotech Co Ltd.
TUG1 F: 5′ TAGCAGTTCCCCAATCCTTG3′; R: 5′
CACAAATTCCCATCAT TCC- C3′; LIMK2b F: 5′
AGGCAGTCACAGACGGATTT3′; R: 5′GAGCTTCC
CATCCT- TCTCATAG 3′; GAPDH was used as an en-
dogenous control. The relative gene expression levels of
TUG1 were determined using the comparative delta-delta
CT method (2-ΔΔCt).
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Cell transfection
SCLC cells were transiently transfected with small inter-
fering siRNA or scrambled siRNA negative control (NC)
. Following the manufacturer’s protocols, cells were seeded
in six-well plates and transfected with siRNA by Lipofecta-
mine 2000 (Invitrogen) when grew to reach about 70% con-
fluence. Three individual TUG1 siRNAs (siTUG1 1*,
siTUG1 2*, siTUG1 3*1), EZH2 siRNA (si-EZH2 1*, si-
EZH2 2*, si-EZH2 3*) and siNC were designed by Gene-
Pharma Inc (Shanghai, China) . The nucleotide sequences
of siRNAs for TUG1 and EZH2 were shown in table S1.
The lentiviral particles of shTUG1 (forward, 5′-
GATCCGCTTGGCTTCTATTCTG AATCCTTTCAAGA
GAAGGATTCAGAATAGAAAGCCAAGCCAAGCTTT
TTTG-3′ and reverse, 5′-GCGAACCGAAGATAA
GACTTAGGAAAGTTCTCTTCCTAA GTCT TATC
TTCGGTTCGAAAAAAC-3′) and LIMK2b-GFP were also
designed and purchased from GenePharma Co., Ltd. To
generate the lenti-viruses, shRNA plasmids were co-
transfected into SCLC cells along with envelope (VSVG)
and packaging (pGag/Pol, pRev) plasmids using lipofecta-
mine 2000 (Invitrogen). The viral supernatants were har-
vested and filtered after 48 h transfection. Cells were
infected in the presence of a serum-containing medium sup-
plemented with 8 μg/ml polybrene. Following infection for
48 h, cells were selected with 2.0 μg/ml puromycin (Sigma).
Knockdown efficiencies were examined by qRT-PCR.
Cell counting kit-8 (CCK-8) assay
Cell proliferation and drug resistance were assayed by the
Cell Counting Kit-8 (CCK8) assay. For cell proliferation
assay, transient transfection cells were seeded in 96-well
plates about 5 × 103 cells per well. According to the manu-
facturer’s protocol, testing cell proliferation every 24 h.
For cell drug resistance assay, after transient transfection
cells, then treated it with drugs for 24 h. Three chemo-
therapy drugs [Cisplatin (DDP; Shandong, China), Adria-
mycin (ADM; Jiangsu, China) Etoposide (VP-16; Jiangsu,
China),] were used. After incubation with 10ul of CCK-8
reagent (Beyotime Institute of Biotechnology, shanghai,
China) for 2 h or 4 h, the absorbance at 450 nm was mea-
sured. The cells incubated without drugs were set at 100%
survival and were used to calculate the concentration of
each chemotherapeutic drug IC50. The assay was per-
formed in five replicate wells, and three parallel experi-
ments for each sample were conducted.
Colony formation assay
Collected cells that transduced with shTUG1, both
shTUG1 and LIMK2b-GFP or control shRNA and
seeded (200 cells/well) in six-well plates. Then, the cells
were incubated in an incubator with 5% CO2 at 37 °C.
After two weeks later, removed the culture medium, and
rinsed cells three times with PBS. Nextly, the cells were
fixed with 4% paraformaldehyde, then stained with 0.1%
crystal violet. The number of colonies were counted by
visual inspection.
Cell invasion and migration assay
For the invasion assays, 24-well Matrigel invasion
chambers
(Corning Incorporated, Corning, NY, USA) was used.
After TUG1 knockdown, 3x104 cells were seeded on the
upper chamber. To stimulate invasion, the bottom cham-
ber was added 500 μL medium with 20% FBS . After 48 h,
cells in the bottom chamber were stained with 0.1% crystal
violet, then counted using a microscopy (100 × magnifica-
tion). Additionally, Wound healing assay was performed
for analysis of cell migration. Cells transfected with either
shTUG1 or shNC, were seeded on six-well plates, then
created an artificial scratch wound with a 100-μl pipette
tip. Cells with serum-free medium for a further 24-h incu-
bation. Recovery of the disruption was observed for 0 h,
24 h. Each assay was performed at least three times.
Flow cytometric analysis
For apoptosis and cell-cycle assay, cells were transfected
with siTUG1, then treated with drugs for 24 h or not
before collected. Cell apoptosis assay was conducted by
using AnnexinV/propidium iodide detection kit
(Keygene, Nanjing, China). For cell-cycle assay, cells
were collected and fixed in 70% ethanol at 4 °C for 16 h
and then stained with propidium iodide.
Tumor xenograft experiments
This study was conducted according to the institutional
guidelines of Guangdong Province and were approved by
the institutional guidelines of Guangdong Province and by
the Use Committee for Animal Care. Male BALB/c nude
mice aged 3–4 weeks were purchased from the Experimen-
tal Animal Center of Sun Yat-sen University (Guangzhou,
China). Cells were harvested and re-suspended in serum
free medium at a concentration of 1 × 107 cells/0.2 ml. Each
mouse was inoculated subcutaneously in the right flank
with SCLC cells stably transduced with shTUG1 or shCon-
trol. Tumor size was monitored every 3 days, and mice
were euthanized after 4 weeks. In vivo chemosensitivity as-
says, the animals were treated with chemotherapeutics or
PBS via intraperitoneal injection (7 mg/kg body weight eto-
poside [once every 2 days] and 3 mg/kg body weight cis-
platin [once every 8 days]).
Western blotting
Equivalent amounts of cell protein lysates were electropho-
resed on an 10% SDS-polyacrylamide gel, transferred to a
PVDF membrane. Then the membrane was incubated with
primary antibodies overnight at 4 °C. Followed incubated by
horseradish peroxidase-labeled secondary antibody. Anti-
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LIMK2b was purchased from Abcam (1:1,000). GAPDH
was used as a protein-loading control. The immune com-
plexes were detected by chemiluminescence (ECL).
RNA immunoprecipitation (RIP) assay
RNA immunoprecipitation was conducted using Magna
RIP RNA-Binding Protein Immunoprecipitation Kit
(Millipore) following the manufacturer’s protocol.
Chromatin immunoprecipitation
The ChIP assays were performed according to the Proto-
col for the fast chromatin immunoprecipitation (ChIP)
method [42]. EZH2 antibody was purchased from
Abcam. H3 trimethyl Lys 27 antibody was from Milli-
pore. Gene specific primers for LIMK2b are listed in
Additional file 5: Table S5. Results were normalized
using the internal control IgG. Precipitated chromatin
DNA was recovered and analyzed by qPCR.
Statistical analysis
Statistical analyses were performed using SPSS version
21.0 software. Experimental results are presented using
means ± SD. Independent- samples T test or one-way
ANOVA were used to analyze the possible differences be-
tween groups. The association between TUG1 expression
and clinical features were analyzed by Pearson Chi-Square
test. Survival curves were assessed by Kaplain-Meier ana-
lysis. Prognostic factors were analyzed by univariate and
multivariate analyses (Cox proportional hazards model). P
values < 0.05 was considered statistically significant.
Additional files
Additional file 1: Figure S1. Relative expression level of TUG1 or EZH2
in H69, H446, H69AR and H446DDP cells transfected with siNC or si-TUG1
or si-EZH2. *, P < 0.05; **, P < 0.001. (TIF 3849 kb)
Additional file 2: Figure S2. TUG1 promoted migration and invasion of
SCLC cells in vitro. (A) Cell migration was quantified by wound healing
assay. Cells were imaged immediately (0 h) and 24 h after scratches were
created to measure the percentage of wound healed area.
Representative images at different time points are shown. (B) Cell
morphology graph of invasive cells in H446, H69AR and H446DDP cells
after stable transfection of shTUG1 or shControl. Data represent mean ±
SD of three independent experiments. (TIF 5658 kb)
Additional file 3: Figure S3. Cell apoptosis and cell cycle were assayed
by flow cytometric analysis after H69 and H446 cells were transfected
with siTUG1. (TIF 6255 kb)
Additional file 4: Figure S4. Apoptosis of H69AR-siTUG1, H446DDP-siTUG1
cells induced by anticancer drugs was significantly increased compared with
controls. (TIF 6733 kb)
Additional file 5: Table S5. qRT-PCR primers. (XLS 20 kb)
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